Personalized medicine, which tailors treatment to an individual's genetic profile, holds great promise for improving cancer outcomes. However, it is still in its infancy, and challenges remain in implementing it widely. These include the high cost of genetic testing, the need for more comprehensive biomarker research, and the integration of personalized approaches into standard care protocols.
